The ibs.GRANADA joins Cancer Prevention Europe, the leading European consortium for cancer prevention
The Granada-based biomedical research institute has been admitted as an affiliate member of the Cancer Prevention Europe consortium, promoted by the International Agency for Research on Cancer (IARC), a WHO agency, to advance cancer research, prevention and early detection in Europe
The Granada Institute for Biomedical Research, ibs.GRANADA, has been admitted as an affiliate member of Cancer Prevention Europe (CPE), a European consortium promoted by the International Agency for Research on Cancer (IARC), a specialized agency of the World Health Organization (WHO), with the aim of strengthening research and international cooperation in cancer prevention.
This addition represents significant recognition of the scientific track record of ibs.GRANADA and the work carried out by its research groups in epidemiology, public health, prevention, early diagnosis, and cancer control. It also strengthens the Institute's participation in national and international collaborative initiatives aimed at reducing the burden of this disease in the population.
Cancer Prevention Europe brings together leading European institutions in the field of cancer prevention. Its activities focus on promoting the generation of scientific evidence, accelerating the transfer of knowledge to health policies, promoting effective prevention strategies, and facilitating early cancer detection.
The admission of ibs.GRANADA will allow the Institute to integrate into a high-level scientific collaboration environment, share knowledge with leading European centers, and contribute to the design of initiatives aimed at improving cancer prevention, reducing health inequalities, and strengthening the application of scientific knowledge in healthcare practice and public policies.
“Becoming part of Cancer Prevention Europe represents recognition of ibs.GRANADA’s commitment to cutting-edge research and generating useful scientific evidence to prevent cancer and improve public health. This membership opens new opportunities for international collaboration and strengthens our institute’s European presence,” says María José Sánchez, Scientific Director of ibs.GRANADA, Professor at the Andalusian School of Public Health, and Director of the Granada Cancer Registry.
Joining this consortium comes at a time when prevention is one of the most effective strategies for reducing cancer incidence and mortality. Available scientific evidence shows that a significant proportion of cases can be avoided through prevention policies, reduction of risk factors, promotion of healthy lifestyles, population-based screening programs, and early detection strategies.
With this addition, ibs.GRANADA consolidates its position as a benchmark in biomedical research and public health, and reinforces its contribution to the major European challenges in the prevention, control and comprehensive approach to cancer.
About the ibs.GRANADA
The ibs.GRANADA Biomedical Research Institute, managed by the Alejandro Otero Foundation for Biomedical Research of Eastern Andalusia (FIBAO), is the only center accredited by the Carlos III Health Institute (ISCIII) that develops biomedical research of excellence in Granada and one of the five accredited in Andalusia by the ISCIII.
The ibs.GRANADA is structured into four Scientific Areas: Oncology, Precision Medicine, Epidemiology and Public Health, and Advanced Technology and Therapies, which carry out intense research activity and lead the transfer of research results to society. This is reflected in the 1.154 publications made in scientific journals (61% of which have been in first quartile journals), which add up to a total of 5.883 impact factor points, as well as 19 patents applied for during the year 2025.
Currently, the Institute brings together more than 1.215 professionals and 75 multidisciplinary research groups that make up, from the University of Granada, the Virgen de las Nieves University Hospital, the San Cecilio Clinical University Hospital, the Andalusian School of Public Health and Primary Care Centers in Granada.
The main objectives of ibs.GRANADA are to promote biomedical, clinical and epidemiological research carried out by the different groups attached to the institute and to facilitate translational research in Granada hospitals. This research activity translates into the generation of knowledge and the transfer of scientific advances towards the prevention, diagnosis and treatment of priority health problems in Andalusia.
More information: http://www.ibsgranada.es
